DESIGN AND ANALYSIS OF BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES

SHEIN-CHUNG CHOW
Biostatistics Department
Bristol-Myers Squibb Company
Plainsboro, New Jersey

JEN-PEI LIU
Biostatistics Department
Berlex Laboratories, Inc.
Wayne, New Jersey

Marcel Dekker, Inc.
New York • Basel • Hong Kong
Contents

Preface iii

1. Introduction 1

1.1 History of Bioavailability Studies 1
1.2 Formulations and Routes of Administration 4
1.3 Pharmacokinetic Parameters 5
1.4 Clinically Important Differences 11
1.5 Assessment of Bioequivalence 12
1.6 Decision Rules and Regulatory Aspects 14
1.7 Statistical Considerations 17
1.8 Aims and Structure of the Book 21

2. Designs of Bioavailability Studies 23

2.1 Introduction 23
2.2 The Study Objective 24
2.3 Basic Design Considerations 26
2.4 The Parallel Design 28
2.5 The Crossover Design 29
2.6 The Balanced Incomplete Block Design 43
2.7 The Selection of Design 46
3. Statistical Inferences for Effects from a Standard 2 × 2 Crossover Design 48
   3.1 Introduction 48
   3.2 The Carry-Over Effects 50
   3.3 The Direct Drug Effect 52
   3.4 The Period Effect 56
   3.5 The Analysis of Variance 59
   3.6 An Example 63

4. Statistical Methods for Average Bioavailability 70
   4.1 Introduction 70
   4.2 The Confidence Interval Approach 72
   4.3 The Methods of Interval Hypotheses Testing 88
   4.4 Bayesian Methods 93
   4.5 Nonparametric Methods 109
   4.6 Discussion and Other Alternatives 119

5. Power and Sample Size Determination 126
   5.1 Introduction 126
   5.2 Hypotheses and Type I and Type II Errors 127
   5.3 Power and Relative Efficiency 134
   5.4 Sample Size Determination 154

6. Transformation and Analysis of Individual Subject Ratios 162
   6.1 Introduction 162
   6.2 Multiplicative (or Log-Transformed) Model 163
   6.3 Bioequivalence Measures 164
   6.4 Maximum Likelihood Estimator 166
   6.5 Minimum Variance Unbiased Estimator 168
   6.6 Mean of Individual Subject Ratios 169
   6.7 Ratio of Formulation Means 172
   6.8 Comparison of MLE, MVUE, MIR, and RM 175
   6.9 An Example 180
   6.10 Discussion 184

7. The Assessment of Inter- and Intra-Subject Variabilities 186
   7.1 Introduction 186
   7.2 Variability and Decision-Making 187
   7.3 Point and Interval Estimates 189
Contents

7.4 Tests for Equality of Variabilities 195
7.5 Equivalence in Variability of Bioavailability 204
7.6 CV Assessment 211
7.7 Discussion 214

8. Assumptions and Outliers Detection 217
   8.1 Introduction 217
   8.2 Tests for Assumptions 218
   8.3 The Definition of Outlying Observations 231
   8.4 Detection of Outlying Subjects 235
   8.5 Detection of Outlying Observations 245
   8.6 Discussion 251

9. Optimal Crossover Designs for Two Formulations 253
   9.1 Introduction 253
   9.2 Balaam's Design 254
   9.3 The Two-Sequence Dual Design 263
   9.4 Optimal Four-Period Designs 272
   9.5 Transformation and Individual Subject Ratios 284
   9.6 Discussion 286

10. Assessment of Bioequivalence for More than Two Formulations 289
    10.1 Introduction 289
    10.2 Assessment of Average Bioavailability with More than Two Formulations 290
    10.3 Analysis for Williams Designs 295
    10.4 Analysis for Balanced Incomplete Block Design 308
    10.5 Discussion 311

11. Assessment of Bioequivalence for Drugs with Negligible Plasma Levels 317
    11.1 Introduction 317
    11.2 Design and Clinical Endpoints 317
    11.3 Statistical Considerations 319
    11.4 Weighted Least Squares Method 324
    11.5 Log-Linear Models 331
    11.6 Generalized Estimating Equations (GEEs) 335
    11.7 Analysis of Time to Onset of a Therapeutic Response 338
    11.8 Discussion 341